(Q43675001)

25 November 2017

title

The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold (English)

1 reference

25 November 2017

Tullis JS

1

1 reference

25 November 2017

Laufersweiler MJ

2

1 reference

25 November 2017

VanRens JC

3

1 reference

25 November 2017

Natchus MG

4

1 reference

25 November 2017

Bookland RG

5

1 reference

25 November 2017

Almstead NG

6

1 reference

25 November 2017

Pikul S

7

1 reference

25 November 2017

De B

8

1 reference

25 November 2017

Hsieh LC

9

1 reference

25 November 2017

Janusz MJ

10

1 reference

25 November 2017

Branch TM

11

1 reference

25 November 2017

Peng SX

12

1 reference

25 November 2017

Jin YY

13

1 reference

25 November 2017

Hudlicky T

14

1 reference

25 November 2017

Oppong K

15

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

Bioorganic & Medicinal Chemistry Letters

25 November 2017

published in

1 reference

25 November 2017

volume

11

1 reference

25 November 2017

issue

15

1 reference

25 November 2017

page(s)

1975-1979

1 reference

Design and therapeutic application of matrix metalloproteinase inhibitors

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900371-7

7 January 2021

Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900371-7

7 January 2021

Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900371-7

7 January 2021

Clinical trials of a stromelysin inhibitor. Osteoarthritis, matrix metalloproteinase inhibition, cartilage loss, surrogate markers, and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900371-7

7 January 2021

Matrix metalloproteinases: biologic activity and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900371-7

7 January 2021

Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900371-7

7 January 2021

Design and synthesis of piperazine-based matrix metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900371-7

7 January 2021

Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900371-7

7 January 2021

Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900371-7

7 January 2021

Chemoenzymatic synthesis of functionalized cyclohexylglycines and alpha-methylcyclohexylglycines via Kazmaier-Claisen rearrangement

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900371-7

7 January 2021

Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900371-7

7 January 2021

Highly enantioselective synthesis of cyclic and functionalized α-amino acids by means of a chiral phase transfer catalyst

1 reference

19 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1016/S0040-4039(98)01067-3

Identifiers

DOI

10.1016/S0960-894X(01)00371-7

1 reference

25 November 2017

1 reference